<DOC>
	<DOCNO>NCT00201994</DOCNO>
	<brief_summary>This study 's purpose determine whether tolvaptan safely effectively return body 's balance sodium water toward normal , characterize quantify potential clinical benefit treatment .</brief_summary>
	<brief_title>`` SALT-2 Trial '' Study Ascending Levels Tolvaptan Hyponatremia</brief_title>
	<detailed_description>Hyponatremia define serum sodium concentration lower limit normal frequently encounter electrolyte abnormality hospitalize patient . Generally speaking , case hyponatremia mild . However , serum sodium fall 130 mEq/L , possibility significant morbidity mortality increase , clinician initiate corrective therapy serum sodium value approach 130 mEq/L low . The reason treat hyponatremia relate symptom , may quite disturb patient , well potential outcome include permanent neurological damage death . also grow awareness association hyponatremia increase mortality patient heart failure . A common theme underlying occurrence hyponatremia whether set congestive heart failure , hepatic failure ascites , syndrome inappropriate anti-diuretic hormone ( SIADH ) non-osmotic secretion arginine vasopressin ( AVP ) . The presence excess AVP lead fluid retention hyponatremia . Agents antagonize AVP , cause proportionally water diuresis solute excretion , could offer significant treatment option patient hyponatremia , compare fluid restriction alone . Treatment hyponatremia , particularly clinical setting decompensated congestive heart failure , difficult conventional diuretic cause neurohormonal activation stimulate inappropriate release vasopressin , lead additional retention free water aggravation hypoosmolality . Similarly , cirrhosis ascites SIADH , conventional diuretic either minimally effective completely contraindicate . An alternative approach symptom relief treatment hyponatremia may use vasopressin antagonist , increase free water clearance proportionally less effect sodium excretion . Tolvaptan oral vasopressin antagonist relative affinity V2 receptor show induce diuresis proportionally free-water sodium loss . The current study undertaken order evaluate whether tolvaptan , oral AVP inhibitor , effective correct mild moderate hyponatremia , elucidate effect correction subject 's well-being .</detailed_description>
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Inappropriate ADH Syndrome</mesh_term>
	<mesh_term>Water-Electrolyte Imbalance</mesh_term>
	<mesh_term>Water Intoxication</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1 . Hyponatremia euvolemic hypervolemic state , define serum sodium &lt; 135 mEq/L prior randomization . 2 . Able give Informed Consent 1 . Women breast feed female childbearing potential use acceptable contraceptive method 2 . Hyponatremia hypovolemic state . 3 . Acute transient hyponatremia associate head trauma postoperative state . 4 . Hyponatremia due uncontrolled hypothyroidism uncontrolled adrenal insufficiency . 5 . Cardiac surgery within 30 day potential study enrollment , exclude percutaneous coronary intervention . 6 . History myocardial infarction within 30 day potential study enrollment . 7 . History sustain ventricular tachycardia ventricular fibrillation within 30 day , unless presence automatic implantable cardioverter defibrillator . 8 . Severe angina include angina rest slight exertion and/or unstable angina . 9 . History cerebrovascular accident within last 30 day . 10 . Subjects psychogenic polydipsia may include , however subject psychiatric illness may include . 11 . Systolic arterial blood pressure &lt; 90 mmHg . 12 . History hypersensitivity and/or idiosyncratic reaction benzazepine benzazepine derivative ( benazepril. ) . 13 . History drug medication abuse within past year , current alcohol abuse . 14 . Uncontrolled diabetes mellitus define fast glucose &gt; 300mg/dL . 15 . Urinary tract obstruction except BPH nonobstructive . 16 . Previous participation another clinical drug trial within past 30 day . 17 . Previous participation tolvaptan clinical trial . 18 . Terminally ill moribund condition little chance short term survival . 19 . Serum creatinine &gt; 3.5 mg/dL . 20 . Serum sodium &lt; 120 mEq/L associate neurologic impairment , i.e . symptom apathy , confusion , seizure . 21 . Patients progressive episodic neurologic disease multiple sclerosis history multiple stroke . 22 . ChildPugh score great 10 ( unless approve ) 23 . Patients receive intravenous fluid rate great KVO ( Keep Vein Open ) . 24 . Hyponatremia due lab artifacts 25 . Patients receive AVP analog treatment condition . 26 . Patients receive within 7 day randomization , medication treatment hyponatremia specifically : demeclocycline , lithium carbonate urea 27 . Patients likely require IV saline correction symptomatic asymptomatic severe hyponatremia course study . 28 . Severe pulmonary artery hypertension 29 . Hyponatremia result medication safely withdrawn</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Sodium</keyword>
	<keyword>SIADH</keyword>
	<keyword>Vasopressin</keyword>
	<keyword>CHF</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>salt</keyword>
	<keyword>water</keyword>
	<keyword>electrolyte</keyword>
</DOC>